Metabolism of glucagon-like peptide-2 in pigs: Role of dipeptidyl peptidase IV

被引:19
|
作者
Hansen, Lene
Hare, Kristine J.
Hartmann, Bolette
Deacon, Carolyn F.
Ugleholdt, Randi K.
Plamboeck, Astrid
Holst, Jens J.
机构
[1] Univ Copenhagen, Panum Inst, Dept Med Physiol, DK-2200 Copenhagen N, Denmark
[2] Univ Copenhagen, Panum Inst, Dept Anat, DK-2200 Copenhagen, Denmark
关键词
valine-pyrrolidide; GLP-2; MCR; DPP-IV;
D O I
10.1016/j.regpep.2006.08.012
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Little is known about the metabolism of the intestinotropic, factor glucagon-like peptide-2 (GLP-2); except that it is a substrate for dipeptidyl peptidase IV (DPP-IV) and that it appears to be eliminated by the kidneys. We, therefore, investigated GLP-2 metabolism in six multicatheterized pigs receiving intravenous GLP-2 infusions (2 pmol/kg/min) before and after administration of valine-pyrrolidide (300 mu mol/kg; a well characterized DPP-IV inhibitor). Plasma samples were analyzed by radioimmunoassays allowing determination of intact, biologically active GLP-2 and the DPP-IV metabolite GLP-2 (3-33). During infusion of GLP-2 alone, 30.9 +/- 1.7% of the infused peptide was degraded to GLP-2 (3-33). After valine-pyrrolidide, there was no significant formation of the metabolite. Significant extraction of intact GLP-2 was observed across the kidneys, the extremities (represented by a leg), and the splanchnic bed, resulting in a metabolic clearance rate (MCR) of 6.80 +/- 0.47 ml/kg/min and a plasma half-life of 6.8 +/- 0.8 min. Hepatic extraction was not detected. Valine-pyrrolidide addition did not affect extraction ratios significantly, but decreased (p=0.003) MCR to 4.18 +/- 0.27 ml/kg/min and increased (p=0.052) plasma half-life to 9.9 +/- 0.8 min. The metabolite was eliminated with a half-life of 22.1 +/- 2.6 min and a clearance of 2.07 +/- 0.11 ml/kg/min. In conclusion, intact GLP-2 is eliminated in the peripheral tissues, the splanchnic bed and the kidneys, but not in the liver, by mechanisms unrelated to DPP-IV. However, DPP-IV is involved in the overall GLP-2 metabolism and seems to be the sole enzyme responsible for N-terminal degradation of GLP-2. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:126 / 132
页数:7
相关论文
共 50 条
  • [1] A kinetic study of glucagon-like peptide-1 and glucagon-like peptide-2 truncation by dipeptidyl peptidase IV, in vitro
    Lambeir, AM
    Proost, P
    Scharpé, S
    De Meester, I
    [J]. BIOCHEMICAL PHARMACOLOGY, 2002, 64 (12) : 1753 - 1756
  • [2] Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 rats and mice
    Hartmann, B
    Thulesen, J
    Kissow, H
    Thulesen, S
    Orskov, C
    Ropke, C
    Poulsen, SS
    Holst, JJ
    [J]. ENDOCRINOLOGY, 2000, 141 (11) : 4013 - 4020
  • [3] Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism
    Lutz, Thomas A.
    Osto, Elena
    [J]. CURRENT OPINION IN LIPIDOLOGY, 2016, 27 (03) : 257 - 263
  • [4] Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV
    Drucker, DJ
    Shi, Q
    Crivici, A
    SumnerSmith, M
    Tavares, W
    Hill, M
    DeForest, L
    Cooper, S
    Brubaker, PL
    [J]. NATURE BIOTECHNOLOGY, 1997, 15 (07) : 673 - 677
  • [5] Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV
    Daniel J. Drucker
    Qing Shi
    Anna Crivici
    Martin Sumner-Smith
    Wendy Tavares
    Mary Hill
    Lorraine DeForest
    Sari Cooper
    Patricia L. Brubaker
    [J]. Nature Biotechnology, 1997, 15 : 673 - 677
  • [6] Glucagon-like peptide-2
    Estall, Jennifer L.
    Drucker, Daniel J.
    [J]. ANNUAL REVIEW OF NUTRITION, 2006, 26 : 391 - 411
  • [7] Glucagon-like peptide-1 and glucagon-like peptide-2
    Baggio, LL
    Drucker, DJ
    [J]. BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 18 (04) : 531 - 554
  • [8] Life in the crypt: A role for glucagon-like peptide-2?
    Rowland, Katherine J.
    Brubaker, Patricia L.
    [J]. MOLECULAR AND CELLULAR ENDOCRINOLOGY, 2008, 288 (1-2) : 63 - 70
  • [9] Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
    Martin C. Michel
    Eric Fliers
    Cornelis J. F. Van Noorden
    [J]. Naunyn-Schmiedeberg's Archives of Pharmacology, 2008, 377 : 205 - 207
  • [10] Dipeptidyl peptidase IV inhibitors in diabetes: more than inhibition of glucagon-like peptide-1 metabolism?
    Michel, Martin C.
    Fliers, Eric
    Van Noorden, Cornelis J. F.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2008, 377 (03) : 205 - 207